NRF2 as an Emerging Therapeutic Target by Copple, Ian M et al.
Editorial
NRF2 as an Emerging Therapeutic Target
IanM. Copple,1 Albena T. Dinkova-Kostova,2 ThomasW. Kensler,3
Karen T. Liby,4 andW. ChristianWigley5
1MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology,
University of Liverpool, Liverpool L69 3GE, UK
2Division of Cancer Research, School of Medicine, University of Dundee, Dundee DD1 9SY, UK
3Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA 15261, USA
4Department of Pharmacology and Toxicology, Michigan State University, East Lansing, MI 48824, USA
5Reata Pharmaceuticals Inc., 2801 Gateway Drive, Irving, TX 75063, USA
Correspondence should be addressed to Ian M. Copple; icopple@liverpool.ac.uk
Received 21 December 2016; Accepted 22 December 2016; Published 31 January 2017
Copyright © 2017 Ian M. Copple et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The transcription factor nuclear factor erythroid 2 related fac-
tor 2 (NRF2) is themaster regulator of the basal and inducible
expression of a large network of cytoprotective genes. As
a result, NRF2 plays a key role in antagonising a range of
pathological insults including reactive oxygen species and
toxic xenobiotics [1]. Consistent with this, dysregulation of
NRF2 signalling is associated with an increased susceptibility
to and/or accelerated progression of a range of experimental
diseases in mice. In recent years, NRF2 has shown promise
as a novel therapeutic target in human diseases, particularly
those with underlying oxidative and inflammatory stress
components [2]. Indeed, several NRF2 inducers have recently
entered the clinic and a number of pharmaceutical companies
have NRF2-based programs. The goal of this special issue is
to highlight the promise of NRF2 as a novel therapeutic target
in a number of disease settings and in turn foster further
research in this burgeoning field.
NRF2 is dysregulated in numerous human pathologies
and thus represents an attractive drug target. A number of
electrophilic NRF2 activators, including naturally occurring
isothiocyanates and semisynthetic triterpenoids, are cur-
rently in clinical trials, and an oral preparation of dimethyl
fumarate (DMF, Tecfidera) is used in clinical practice to
reduce disease progression in patients with relapsing remit-
ting multiple sclerosis. In multiple sclerosis, neuronal degen-
eration is linked to glutamate-induced excitotoxicity and
oxidative stress, and it has been reported that DMF protects
cells against the neurotoxicity of glutamate [3, 4]. In this
special issue, C. Hoffmann et al. show that one of the
consequences of exposure of cells to DMF is an increase
in glutathione recycling by induction of the NRF2 tran-
scriptional target glutathione reductase, the enzyme which
catalyzes the regeneration of oxidized glutathione (GSSG)
to its reduced (GSH) form. Curiously, however, inhibition
(genetic or pharmacological) of glutathione reductase has
a synergistic protective effect to that of DMF. The authors
further show that this protection correlates with activation of
a number of NRF2-dependent genes. These findings confirm
the critical cytoprotective role of glutathione, the most abun-
dant intracellular antioxidant, and illustrate the versatility
and robustness of NRF2-mediated cytoprotection.
Two papers in this special issue highlight the protective
effect of NRF2 in the eye. K. Takayama et al. describe a role
for NRF2 in protection against blue light retinal pigment
epithelial (RPE) cell damage. Specifically, the authors show
that blue light exposure (450 nm) stimulates reactive oxygen
species generation and NRF2 signalling in a human RPE
cell line, and that primary RPE cells from transgenic Nrf2
knockout mice are more sensitive to blue light induced cell
death compared with cells from wild type mice.
Using a pharmacological approach, X. Xu et al. show
that the flavonoid apigenin protects a human RPE cell line
against tert-butyl hydroperoxide-induced oxidative stress
and cell death via the stimulation of NRF2 signalling, with
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the protective effect abolished following siRNA knockdown
ofNRF2.The findings of these studies are consistent with pre-
vious work showing that aged Nrf2 knockout mice develop
ocular pathology with similar features to human age-related
muscular degeneration, a leading cause of blindness [5].
These and other preclinical studies highlight the potential of
NRF2 as a novel therapeutic target in ocular disease, andmay
inform future clinical trials in this area.
Angiotensin II (Ang II) is a vasoconstrictive hormone
and a key component of the renin-angiotensin system, which
regulates vascular tone and blood pressure. Although largely
associatedwith effects on vascular smoothmuscle and kidney
epithelia, receptors for Ang II are present in testes, suggesting
a potential role in male fertility. S.-J. Wang et al. have con-
tributed with an interesting study assessing the effects of
Ang II on testicular cell viability and the potential impact
of Nrf2 induction with the isothiocyanate sulforaphane. In
wild type and Nrf2 knockout mice, treatment with Ang
II was associated with testicular weight loss, oxidative and
endoplasmic reticulum stress, inflammation, and apoptotic
cell death. Treatment with sulforaphane was protective in
wild type mice but not in those lacking Nrf2, demonstrating
the Nrf2-dependence of the efficacy. These results further
illustrate the importance of Nrf2 in male fertility and provide
additional insights into the influence of Ang II signalling on
testicular health and function.
Our expanding knowledge of the regulatory influences on
NRF2 activity continues to informnew strategies for targeting
the transcription factor beyond the use of electrophilic agents
that have the ability to modify critical cysteine residues
in KEAP1, the redox-sensitive repressor of NRF2. Indeed,
compounds and peptides that disrupt the binding interface
between NRF2 and KEAP1 have been described [6] and
may represent an important alternative therapeutic approach
given the propensity of some electrophiles to react with
unintended targets. In their review, H. Yukitake et al. high-
light the role of macrophage migration inhibitory factor
(MIF) as a regulator of NRF2-driven gene expression. The
authors describe how a chemical screening process identified
the cardioprotective agent BTZO-1, which was subsequently
found to augment the expression of NRF2-regulated genes
in a MIF-dependent manner, similarly to recombinant MIF
protein. In proposing that MIF is an alternative sensor for
electrophilic NRF2 activators, H. Yukitake et al. highlight the
importance of appreciating the selectivity of small molecules
that target NRF2 and other signalling pathways, particularly
for understanding the role of NRF2 per se in the therapeutic
effects of a given compound.
Zebrafish (Danio rerio) are an important and widely used
vertebrate model organism for studies on development and
gene function. Using this model, the Kobayashi laboratory
has described previously the evolutionary conservation of
Keap1-Nrf2 signalling in defence against oxidative and elec-
trophilic stresses. Herein, V. T. Nguyen et al. describe the con-
duct of a microarray analysis of zebrafish embryos that either
overexpressed Nrf2 or were challenged with small molecule
activators of the pathway. These genetic and pharmacologic
approaches demonstrate that additional functions of the
Nrf2 pathway, namely, the regulation of protein turnover
and glucose metabolism that have been observed in higher
vertebrates, are conserved in zebrafish. These results provide
further support for the notion that the key actions of
Nrf2 extend far beyond, evolutionarily and functionally, its
canonical actions of affecting xenobioticmetabolism. Indeed,
actions on protein turnover and glucose metabolism may be
central to the evolutionary development of this important
signalling pathway.
In summary, this special issue highlights recent advances
in our understanding of the regulatory mechanisms, physio-
logical roles, and cytoprotective effects of NRF2 in a range
of preclinical models. At present, the benefits and risks of
modulating NRF2 pathway activity in patients are not fully
understood, and it is known that NRF2 and KEAP1 may
cross-talk with other signalling pathways, such as NF-𝜅B.
Indeed, many NRF2 inducers directly influence the activities
of these pathways, and thus it will be important to establish
the true therapeutic value ofmodulatingNRF2 per se inman.
However, with an expanding number of compounds entering
clinical trials, the field should be well-placed to answer these
and other pertinent questions.
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